Preliminary Japan switch-OTC nod a boon for under-pressure Epadel
This article was originally published in Scrip
A review committee of Japan's ministry of health, labour and welfare has recommended the approval of a prescription to over-the-counter switch version of Mochida's fish oil-derived product Epadel (ethyl icosapentate), for the treatment of hyperlipidaemia.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.